Trial · NCT00740051
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| HbA1c Change From Baseline at Week 18 (Interim Analysis) | Placebo | 0.14 | Standard Error 0.16 | percent | |
| HbA1c Change From Baseline at Week 18 (Interim Analysis) | Linagliptin | -0.44 | Standard Error 0.14 | percent | |
| HbA1c Change From Baseline at Week 18 (Final Analysis) | Placebo | 0.21 | Standard Error 0.16 | percent | |
| HbA1c Change From Baseline at Week 18 (Final Analysis) | Linagliptin | -0.39 | Standard Error 0.14 | percent | |
| Fasting Plasma Glucose (FPG) Change From Baseline at Week 18 (Interim Analysis) | Placebo | 7.2 | Standard Error 6.0 | mg/dl | |
| Fasting Plasma Glucose (FPG) Change From Baseline at Week 18 (Interim Analysis) | Linagliptin | -13.3 | Standard Error 5.2 | mg/dl | |
| Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis) | Placebo | 11.8 | percent of patients | ||
| Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis) | Linagliptin | 23.5 | percent of patients | ||
| Percentage of Patients With HbA1c<6.5 at Week 18 (Interim Analysis) | Placebo | 2.9 | percent of patients | ||
| Percentage of Patients With HbA1c<6.5 at Week 18 (Interim Analysis) | Linagliptin | 8.9 | percent of patients | ||
| Percentage of Patients With HbA1c Lowering by 0.5% at Week 18 (Interim Analysis) | Placebo | 17.8 | percent of patients | ||
| Percentage of Patients With HbA1c Lowering by 0.5% at Week 18 (Interim Analysis) | Linagliptin | 36.1 | percent of patients | ||
| The Change in HbA1c From Baseline by Visit Over Time | Placebo/Glimepiride | Change from baseline at week 6 (N=64, 136) | 0.26 | Standard Deviation 0.98 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Linagliptin | Change from baseline at week 6 (N=64, 136) | -0.21 | Standard Deviation 0.77 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Placebo/Glimepiride | Change from baseline at week 12 (N=57, 129) | 0.26 | Standard Deviation 1.08 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Linagliptin | Change from baseline at week 12 (N=57, 129) | -0.43 | Standard Deviation 0.84 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Placebo/Glimepiride | Change from baseline at week 18 (N=47, 118) | 0.10 | Standard Deviation 1.06 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Linagliptin | Change from baseline at week 18 (N=47, 118) | -0.38 | Standard Deviation 0.87 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Placebo/Glimepiride | Change from baseline at week 22 (N=46, 113) | -0.32 | Standard Deviation 0.82 | percent |
| The Change in HbA1c From Baseline by Visit Over Time | Linagliptin | Change from baseline at week 22 (N=46, 113) | -0.40 | Standard Deviation 0.94 | percent |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00740051/results